Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
Read Article
News
2025
2024
Archive
Search news articles
February 6, 2025
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
December 13, 2024
Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
December 11, 2024
Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
December 10, 2024
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
December 9, 2024
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
December 9, 2024
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
December 4, 2024
Nido Biosciences Announces Publication of Collaborative Research Revealing Clinically Meaningful Endpoints for Spinal and Bulbar Muscular Atrophy
December 3, 2024
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer
November 21, 2024
Cidara Therapeutics Announces $105 Million Private Placement
November 21, 2024
Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
1
2
3
…
124
Next Page »